Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment

Summary

The goal of this clinical trial is to explore the potential of metformin in managing olanzapine-induced metabolic disturbance and hyperprolactinemia in patients with schizophrenia. The main questions it aims to answer are: 1. The effect of metformin on olanzapine-induced metabolic disturbance 2. The effect of metformin on olanzapine-induced hyperprolactinemia Participants will receive metformin 1500 mg/day for 8 weeks and assessments every 2 weeks.

Timeline

Start

2010-05-31

Primary completion

2011-06-10

Completion

2011-06-10

Drugs

Indications